Comparative Pharmacology
Head-to-head clinical analysis: CARBINOXAMINE MALEATE versus CLARINEX D 12 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARBINOXAMINE MALEATE versus CLARINEX D 12 HOUR.
CARBINOXAMINE MALEATE vs CLARINEX-D 12 HOUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbinoxamine maleate is a first-generation antihistamine that competitively inhibits histamine at H1 receptors, thereby preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also exhibits anticholinergic and sedative properties.
Desloratadine is a long-acting tricyclic histamine antagonist selective for H1-receptor with additional anti-inflammatory properties. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors.
Adults: 4-8 mg orally every 6-8 hours as needed. Maximum: 24 mg/day.
1 tablet (5 mg desloratadine / 120 mg pseudoephedrine) orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment, requiring dose adjustment in significant liver disease.
Desloratadine: 27 hours (terminal), allows once-daily dosing; pseudoephedrine: 4-6 hours (prolonged in alkaline urine).
Primarily renal excretion of metabolites and unchanged drug; ~60-70% of a dose is excreted in urine within 48 hours, with less than 5% as unchanged drug. Biliary/fecal elimination accounts for a minor fraction (<10%).
Desloratadine: 40.2% renal (unchanged and metabolites), 41.7% fecal; pseudoephedrine: 70-90% renal (unchanged).
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination